key: cord-0946880-95cljes3 authors: Saade, Anastasia; Cha, Leo; Tadié, Emilie; Jurado, Bruno; Le Bihan, Alix; Baron-Latouche, Pauline; Febreau, Christine; Thibault, Vincent; Garlantezec, Ronan; Tattevin, Pierre; Paris, Christophe title: Delay between COVID-19 complete vaccination and SARS-CoV-2 infection among healthcare workers date: 2022-04-18 journal: Vaccine DOI: 10.1016/j.vaccine.2022.04.045 sha: b385017f421c1bfc5f726f42f07eaf50fe1eed72 doc_id: 946880 cord_uid: 95cljes3 OBJECTIVES: Healthcare workers (HCWs), at increased risk of coronavirus disease 2019 (COVID-19) were among the primary targets for vaccination, which became mandatory for them on September 15(th), 2021 in France. In November they were confronted to the fifth COVID-19 wave despite excellent vaccine coverage. We aimed to estimate the incidence of SARS-CoV-2 infection after complete vaccination among HCWs with different vaccination schemes, and its determinants. METHODS: We enrolled all HCWs in the university hospital of Rennes, France who had received complete vaccination (two doses of COVID-19 vaccine). The delay from last vaccination dose to SARS-CoV-2 infection was computed. Fitted mixed Cox survival model with a random effect applied to exposure risk periods to account for epidemic variation was used to estimate the determinants of SARS-CoV-2 infection after complete vaccination. RESULTS: Of the 6674 (82%) HCWs who received complete vaccination (36% BNT162b2, 29% mRNA-1273, and 34% mixed with ChAdOx1 nCoV-19) and were prospectively followed-up for a median of 7.0 [6.3-8.0] months, 160 (2.4%) tested positive for SARS-CoV-2 by RT-PCR. Incidence density of SARS-CoV-2 infection after complete vaccination was 3.39 [2.89-3.96] infections per 1000 person-month. Median time from vaccine completion to SARS-CoV-2 infection was 5.5 [3.2-6.6] months. Using fitted mixed Cox regression with the delay as a time-dependent variable and random effect applied to exposure risk periods, age (P<0.001) was independently associated with the incidence of SARS-CoV-2 infection. Vaccine schemes were not associated with SARS-CoV-2 infection (P=0.068). A period effect was significantly associated with the incidence of SARS-CoV-2 infection (P<0.001). CONCLUSIONS: In this real-world study, incidence of SARS-CoV-2 infection increases with time in fully vaccinated HCWs with no differences according to the vaccination scheme. The short delay between complete vaccination and incident SARS-CoV-2 infection highlights the need for sustained barrier measures even in fully vaccinated HCWs. Healthcare workers (HCWs) are at increased risk for exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to their interactions with patients in addition to their household and community (1) . In France, COVID-19 vaccines have been available since January 2021, with priority initially given to individuals at high risk of severe coronavirus disease 2019 (COVID-19), and HCWs. At that time, the alpha variant was predominant and responsible for the third wave. From June, the Delta variant progressively replaced the alpha variant to become predominant in July 2020, responsible for the fourth wave followed by the fifth wave wave. We performed a prospective monocentric cohort study to evaluated the risk of SARS-CoV-2 infection and assess its determinants among fully vaccinated HCWs. We performed a monocentric prospective cohort study in the university hospital of Two prospective databases systematically recorded in our institution were merged: (a) HCWs who received complete COVID-19 vaccination as previously described (2) . To account for variations in the infection rate and variant circulation throughout the study period, a time-dependent fitted mixed Cox model was performed using i) random effect applied to the different exposure risk periods to account for the following risk throughout the COVID-19 waves, and ii) delay from complete vaccination to SARS-CoV-2 infection as a time-dependent variable, to assess risk factors associated with positivity for SARS-CoV-2 after complete vaccination. Exposure risk periods were defined according to the month last vaccine dose was received. HCWs who received their last dose in November and December were considered as exposed to the same risk (fifth wave). Variables were selected if significant (P<0.2) in the univariate analysis ( We Interestingly, age was independently associated with the incidence of SARS-CoV-2 infection with younger HCWs at increased risk of infection in our study. This observation might be explained by the fact that younger HCWs are more exposed and may take more risk with reduced barrier measures. Our study has limitations. First, as a monocentric study, its findings may not be generalizable to other settings, given the variability of the epidemiology of SARS-CoV-2 variants. In addition, our results might not extrapolate to the Omicron variant. However, our study includes homogeneous data with appropriate follow-up and data vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet Lond Engl COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study. Vaccine Waning Immunity after the BNT162b2 Vaccine in Israel Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland COVID-19 breakthrough infection and post-vaccination neutralizing antibody among healthcare workers in a referral hospital in Tokyo: a case-control matching study We declare no conflict of interest related to this work. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. ☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:We declare no conflict of interest related to the submitted work.